| Dr Rawa Sarji, DO | |
|
350 Heritage Way, Suite 2100, Kalispell, MT 59901-3158 | |
| (406) 257-8992 | |
| Not Available |
| Full Name | Dr Rawa Sarji |
|---|---|
| Gender | Female |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 19 Years |
| Location | 350 Heritage Way, Kalispell, Montana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396978128 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Rochester General Hospital | Rochester, NY | Hospital |
| United Memorial Medical Center | Batavia, NY | Hospital |
| Newark-wayne Community Hospital | Newark, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Rochester General Hospital | 0244149474 | 891 |
News Archive
On Wednesday, March 21, the Congressional Brain Injury Task Force brings representatives from the brain injury community to Capitol Hill for Brain Injury Awareness (BIA) Day. The day starts with the BIA Fair, where attendees share information on policy issues, research, diagnosis and screening and care and rehabilitation. The afternoon features a briefing on "The Impact of Brain Injury: Any Time, Any One, Any Age."
Prior Scientific's Z-Deck range is a high quality, height adjustable platform designed specifically for upright microscopes widely used in electrophysiology and neuroscience, including the Nikon FN1/Ni, the Olympus BX51WI / BX61WI, and the Zeiss Axio Examiner microscopes.
Alnylam Pharmaceuticals, Inc. has announced new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis).
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) to update the current label of XELJANZ® (tofacitinib citrate) 5 mg tablets to include radiographic data from two Phase 3 studies, ORAL Scan (A3921044) and ORAL Start.
Newsweek in its Oct. 6 issue examines malaria eradication efforts and the Global Malaria Action Plan, which aims to eradicate malaria worldwide and was released last week during the United Nations General Assembly High-Level Meeting on the U.N. Millennium Development Goals (Carmichael/Cunningham, Newsweek, 10/6).
› Verified 2 days ago
| Entity Name | Rochester General Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356412712 PECOS PAC ID: 0244149474 Enrollment ID: O20031121000644 |
News Archive
On Wednesday, March 21, the Congressional Brain Injury Task Force brings representatives from the brain injury community to Capitol Hill for Brain Injury Awareness (BIA) Day. The day starts with the BIA Fair, where attendees share information on policy issues, research, diagnosis and screening and care and rehabilitation. The afternoon features a briefing on "The Impact of Brain Injury: Any Time, Any One, Any Age."
Prior Scientific's Z-Deck range is a high quality, height adjustable platform designed specifically for upright microscopes widely used in electrophysiology and neuroscience, including the Nikon FN1/Ni, the Olympus BX51WI / BX61WI, and the Zeiss Axio Examiner microscopes.
Alnylam Pharmaceuticals, Inc. has announced new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis).
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) to update the current label of XELJANZ® (tofacitinib citrate) 5 mg tablets to include radiographic data from two Phase 3 studies, ORAL Scan (A3921044) and ORAL Start.
Newsweek in its Oct. 6 issue examines malaria eradication efforts and the Global Malaria Action Plan, which aims to eradicate malaria worldwide and was released last week during the United Nations General Assembly High-Level Meeting on the U.N. Millennium Development Goals (Carmichael/Cunningham, Newsweek, 10/6).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Rawa Sarji, DO 350 Heritage Way, Suite 2100, Kalispell, MT 59901-3158 Ph: (406) 257-8992 | Dr Rawa Sarji, DO 350 Heritage Way, Suite 2100, Kalispell, MT 59901-3158 Ph: (406) 257-8992 |
News Archive
On Wednesday, March 21, the Congressional Brain Injury Task Force brings representatives from the brain injury community to Capitol Hill for Brain Injury Awareness (BIA) Day. The day starts with the BIA Fair, where attendees share information on policy issues, research, diagnosis and screening and care and rehabilitation. The afternoon features a briefing on "The Impact of Brain Injury: Any Time, Any One, Any Age."
Prior Scientific's Z-Deck range is a high quality, height adjustable platform designed specifically for upright microscopes widely used in electrophysiology and neuroscience, including the Nikon FN1/Ni, the Olympus BX51WI / BX61WI, and the Zeiss Axio Examiner microscopes.
Alnylam Pharmaceuticals, Inc. has announced new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis).
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) to update the current label of XELJANZ® (tofacitinib citrate) 5 mg tablets to include radiographic data from two Phase 3 studies, ORAL Scan (A3921044) and ORAL Start.
Newsweek in its Oct. 6 issue examines malaria eradication efforts and the Global Malaria Action Plan, which aims to eradicate malaria worldwide and was released last week during the United Nations General Assembly High-Level Meeting on the U.N. Millennium Development Goals (Carmichael/Cunningham, Newsweek, 10/6).
› Verified 2 days ago
Dr. Tobin James Hoppes, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 75 Claremont St Ste H, Kalispell, MT 59901 Phone: 406-752-7406 Fax: 406-752-7544 | |
Marise K Johnson, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1280 Burns Way, Kalispell, MT 59901 Phone: 406-755-5266 Fax: 406-755-0228 | |
Kerry J Eby, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 310 Sunnyview Ln, Kalispell, MT 59901 Phone: 406-751-6725 | |
Dr. Jeffrey W. Watkins, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 350 Heritage Way Ste 2100, Kalispell, MT 59901 Phone: 406-257-8992 Fax: 406-275-8996 | |
Torbjorn Ingvar Joreteg, MD PHD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 160 Heritage Way, Kalispell, MT 59901 Phone: 406-755-7785 Fax: 406-755-7857 | |
Nathaniel Lyle Hall, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 350 Heritage Way, Suite 2100, Kalispell, MT 59901 Phone: 406-257-8992 Fax: 406-751-4161 | |
Anna Rose Robbins, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 310 Sunnyview Ln, Northwest Hospitalists, Kalispell, MT 59901 Phone: 406-751-5310 Fax: 406-751-5769 |